Revolution Medicines Inc faces a notable decline as biotech stocks struggle in a turbulent market.
Revolution Medicines Inc (NASDAQ:RVMD) experienced a significant drop of 1.53% in its stock price today, closing at CA$190.99. This downturn aligns with a broader trend impacting biotech stocks, which have faced recent turbulence.
Investor takeaway: Investors should closely monitor Revolution Medicines' performance amid ongoing volatility in the biotech sector, particularly as it navigates the aftermath of FDA approvals and the launch of pivotal trials.
Advertisement
Revolution Medicines Inc
RVMD.US
RVMD.US
Revolution Medicines Inc
WealthAwesomeMarket cap
$40.67B
52W high
$224.31
52W low
$47.45
1W change
-6.61%
Beta
1.40
Analyst Price Targets
Based on 24 analysts covering RVMD · as of Oct 12, 2026
Wall Street analysts forecast RVMD stock price to rise 33.6% over the next 12 months.
Consensus
Strong Buy4.71 / 5.00
Avg. Target
C$259.14
+33.6% Upside
Previously C$258.84 on Oct 8, 2026
Current Price
C$193.95
Last close
Analyst Breakdown (24 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RVMD's historical volatility
30-Day Vol
34.9%
Annualized
90-Day Vol
39.2%
Annualized
Trend (90d)
+17.2%
Annualized drift
90d Mean
C$206.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$197.97 | C$175.53 – C$223.27 |
| 60 trading days | C$202.07 | C$170.45 – C$239.54 |
| 90 trading days | C$206.25 | C$167.46 – C$254.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Revolution Medicines recently secured FDA approval for its breakthrough cancer drug Rasonque. This approval could lead to future revenue growth and expansion in the market.
Bear case
The recent decline in stock price reflects broader market pressures on biotech stocks. This raises concerns about the sustainability of Revolution Medicines' growth, especially given the increasing cash burn and clinical risks.
Market Context
The biotech sector has seen significant volatility recently, with stocks like Revolution Medicines, Moderna, and Vaxcyte among the biggest losers. This broader market trend has raised concerns about the sustainability of growth in the sector, particularly for companies with high cash burn rates and ambitious clinical trials.
Advertisement
Recent Developments
Despite the stock's decline, Revolution Medicines recently received FDA approval for its cancer drug Rasonque, marking a significant milestone. The company's CEO, Mark Goldsmith, has emphasized a commitment to ensuring access for all eligible patients, which could enhance the company's reputation and market position in the long run.
Investor Sentiment
The current market sentiment surrounding Revolution Medicines is mixed. While the FDA approval is a positive development, the ongoing decline in stock price suggests that investors are cautious about the company's ability to manage its cash burn and execute on its clinical trials, particularly with the launch of the pivotal RASolute 309 trial.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
